Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.66 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 6/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168974 | 0.85 | GABRA1 (0.79) | GABRA1GABRB2KMT2AMEN1MAPT | |
| SCHEMBL430886 | 0.80 | CA2 (0.43) | GABRA1GABRB2KMT2AMEN1MAPT | |
| SCHEMBL16933817 | 0.79 | GABRA1 (0.48) | GABRA1GABRB2KMT2AMEN1MAPT | |
| SCHEMBL1258090 | 0.79 | GABRA1 (1.00) | GABRA1GABRB2KMT2AMEN1MAPT | |
| SCHEMBL30817860 | 0.79 | GABRA1 (0.70) | GABRA1GABRB2KMT2AMEN1MAPT | |
| SCHEMBL346369 | 0.79 | GABRA1 (0.70) | GABRA1GABRB2KMT2AMEN1MAPT | |
| SCHEMBL836026 | 0.79 | GABRA1 (0.70) | GABRA1GABRB2KMT2AMEN1MAPT | |
| SCHEMBL2475077 | 0.79 | GABRA1 (0.47) | GABRA1GABRB2KMT2AMEN1MAPT | |
| SCHEMBL30083989 | 0.79 | GABRA1 (0.47) | GABRA1GABRB2KMT2AMEN1MAPT | |
| SCHEMBL5659189 | 0.78 | GABRA1 (0.63) | GABRA1GABRB2KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729516-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2026-04-22 | — | — | EP | disclosed |
| US-20250289793-A1 | MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE | ESPERION THERAPEUTICS, INC. | 2025-09-18 | — | — | US | disclosed |
| EP-4519251-A1 | MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE | Esperion Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| WO-2024260319-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏恩华药业股份有限公司 | 2024-12-26 | — | — | WO | disclosed |
| CN-119137107-A | Macrocyclic inhibitors of ATP citrate lyase | 艾斯柏伦治疗公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2023215220-A1 | MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE | ESPERION THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| EP-4058435-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| US-20220281819-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| CN-114728905-A | Therapeutic compounds and methods of use | 基因泰克公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021097110-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | disclosed |
| EP-0433746-B1 | Thermoplastic flame retardant silicone polyphenylene ether graft copolymers | GEN ELECTRIC (US) | 1995-03-22 | — | — | EP | disclosed |
| US-5281686-A | Oxidative coupling 2,6-dialkylphenol to monophenol substituted polysiloxane | GENERAL ELECTRIC COMPANY (US) | 1994-01-25 | — | — | US | disclosed |
| US-5204438-A | Silicone macromers and thermoplastic flame retardant silicone-polyphenylene ether graft copolymers obtained therefrom | GENERAL ELECTRIC COMPANY (US) | 1993-04-20 | — | — | US | disclosed |
| EP-0515196-A2 | Method for making silicone polyphenylene ether graft copolymers and products | GENERAL ELECTRIC COMPANY (US) | 1992-11-25 | — | — | EP | disclosed |
| EP-0433746-A2 | Thermoplastic flame retardant silicone polyphenylene ether graft copolymers | GENERAL ELECTRIC COMPANY (US) | 1991-06-26 | — | — | EP | disclosed |
| EP-0088619-A2 | Benzopyrans | THE UPJOHN COMPANY (US) | 1983-09-14 | — | — | EP | disclosed |
| US-4401824-A | Benzopyran compounds, derivatives of prostaglandins | THE UPJOHN COMPANY (US) | 1983-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281819-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, NQO1, PCSK9 | GABRA1 3883/4885GABRB2 3279/4885KMT2A 2487/4885 |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | HTR2C, HTR1A, HTR3A | GABRA1 123/4885GABRB2 184/4885KMT2A 2254/4885 |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | ADRA2A, HTR2A, ADRA1A | GABRA1 243/4885GABRB2 279/4885KMT2A 506/4885 |
| US-20250289793-A1 | MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE | ACLY, CS, ATP5ME | GABRA1 2496/4885GABRB2 1639/4885KMT2A 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.